ADC Therapeutics SA (ADCT)
ADC Therapeutics SA Statistics
Share Statistics
ADC Therapeutics SA has 96.69M shares outstanding. The number of shares has increased by 17.16% in one year.
| Shares Outstanding | 96.69M |
| Shares Change (YoY) | 17.16% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 52.36% |
| Shares Floating | 75.93M |
| Failed to Deliver (FTD) Shares | 4.04K |
| FTD / Avg. Volume | 0.42% |
Short Selling Information
The latest short interest is 5.18M, so 5.36% of the outstanding shares have been sold short.
| Short Interest | 5.18M |
| Short % of Shares Out | 5.36% |
| Short % of Float | 6.68% |
| Short Ratio (days to cover) | 5.96 |
Valuation Ratios
The PE ratio is -0.57 and the forward PE ratio is -1.15. ADC Therapeutics SA's PEG ratio is -0.01.
| PE Ratio | -0.57 |
| Forward PE | -1.15 |
| PS Ratio | 1.95 |
| Forward PS | 0.5 |
| PB Ratio | -0.91 |
| P/FCF Ratio | -1.11 |
| PEG Ratio | -0.01 |
Enterprise Valuation
ADC Therapeutics SA has an Enterprise Value (EV) of -18.58M.
| EV / Earnings | 0.08 |
| EV / Sales | -0.27 |
| EV / EBITDA | 0.13 |
| EV / EBIT | 0.11 |
| EV / FCF | 0.15 |
Financial Position
The company has a current ratio of 4.97, with a Debt / Equity ratio of -0.84.
| Current Ratio | 4.97 |
| Quick Ratio | 4.73 |
| Debt / Equity | -0.84 |
| Total Debt / Capitalization | -521.02 |
| Cash Flow / Debt | -0.95 |
| Interest Coverage | -3.58 |
Financial Efficiency
Return on equity (ROE) is 1.62% and return on capital (ROIC) is 834.46%.
| Return on Equity (ROE) | 1.62% |
| Return on Assets (ROA) | -0.68% |
| Return on Capital (ROIC) | 834.46% |
| Revenue Per Employee | $254,791.21 |
| Profits Per Employee | $-879,315.02 |
| Employee Count | 273 |
| Asset Turnover | 0.2 |
| Inventory Turnover | 0.16 |
Taxes
| Income Tax | 39.11M |
| Effective Tax Rate | -0.2 |
Stock Price Statistics
The stock price has increased by -65.66% in the last 52 weeks. The beta is 1.54, so ADC Therapeutics SA's price volatility has been higher than the market average.
| Beta | 1.54 |
| 52-Week Price Change | -65.66% |
| 50-Day Moving Average | 1.76 |
| 200-Day Moving Average | 2.72 |
| Relative Strength Index (RSI) | 46.18 |
| Average Volume (20 Days) | 953.34K |
Income Statement
In the last 12 months, ADC Therapeutics SA had revenue of 69.56M and earned -240.05M in profits. Earnings per share was -2.94.
| Revenue | 69.56M |
| Gross Profit | 67.03M |
| Operating Income | -165.99M |
| Net Income | -240.05M |
| EBITDA | -146.76M |
| EBIT | -165.99M |
| Earnings Per Share (EPS) | -2.94 |
Balance Sheet
The company has 278.6M in cash and 124.38M in debt, giving a net cash position of 154.22M.
| Cash & Cash Equivalents | 278.6M |
| Total Debt | 124.38M |
| Net Cash | 154.22M |
| Retained Earnings | -1.34B |
| Total Assets | 349.08M |
| Working Capital | 265.33M |
Cash Flow
In the last 12 months, operating cash flow was -118.69M and capital expenditures -3.22M, giving a free cash flow of -121.9M.
| Operating Cash Flow | -118.69M |
| Capital Expenditures | -3.22M |
| Free Cash Flow | -121.9M |
| FCF Per Share | -1.49 |
Margins
Gross margin is 96.36%, with operating and profit margins of -238.63% and -345.11%.
| Gross Margin | 96.36% |
| Operating Margin | -238.63% |
| Pretax Margin | -280.94% |
| Profit Margin | -345.11% |
| EBITDA Margin | -210.99% |
| EBIT Margin | -238.63% |
| FCF Margin | -175.25% |
Dividends & Yields
ADCT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -184.91% |
| FCF Yield | -79.04% |
Analyst Forecast
The average price target for ADCT is $8, which is 403.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $8 |
| Price Target Difference | 403.1% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -5.66 |
| Piotroski F-Score | 2 |